

Disclosure of conflict of interest

Faculty members have been asked to disclose any potential conflict of interest in relation to their participation in the above mentioned event. Potential conflict of interest are considered any of the following:

- Any financial interest in or arrangement with a company whose products or services are discussed in the lecture or that might be considered as part of the statement process;
- Any financial interest in or arrangement with a competing company;
- Any other financial relationship, direct or indirect, or other situations that might raise the question of bias in the work presented or in the participation in the statement process, including pertinent commercial or other sources of funding for the speaker or panellist or for the associated department or organisation, personal relationships or direct academic competition.

S. Aguilar: *No significant relationships*

G. Apolone: *No significant relationships*

G. Ciliberto: *Form not received*

P. De Paoli: *No significant relationships*

C. Grau: *No significant relationships*

R. Herold: *No significant relationships*

M. Kamal:

Recipient of honoraria or consultation fees: AZD, Roche

U. Lassen:

Recipient of grants/research supports: BMS, Roche, GSK, Pfizer, Incyte, Lilly, J&J, Novartis

Recipient of honoraria or consultation fees: Advisory board: Bayer, Novartis, Pfizer

J. Lovey: *No significant relationships*

I. Lugowska: *Form not received*

P. Nagy: *No significant relationships*

S. Oberst: *No significant relationships*

U. Pastorino: *No significant relationships*

J. Poleszczuk:

Stock/shareholder: CliniNote Sp. z o.o.

P. Rutkowski:

Recipient of grants/research supports: Pfizer

Recipient of honoraria or consultation fees: MSD, BMS, Novartis, Pierre Fabre, Sanofi, Merck, Genesis Pharma, Medison Pharma, Philogen

Participation in a sponsored speakers' bureau: Pierre Fabre, Philogen

K. Taskén:

Recipient of grants/research supports: Illumina, AstraZeneca, Roche, Novartis, InCyte, Eli Lilly, Merck, GSK - to the IMPRESS-Norway trial through our hospital